Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA)

Q: What does CUSIP 877619106 represent in this 13F holders report?

CUSIP 877619106 is the security identifier for TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share used to aggregate holder disclosures.

Q: How many institutions held TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share in Q1 2023?

42 institutional investors reported TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share for Q1 2023. Use the holders table for investor-level position and value details.

CUSIP: 877619106

Q1 2023 13F Holders as of 31 Mar 2023

Security type / class: Equity / Common Stock, $0.00001 par value per share
Total 13F shares: 16,687,605
Total 13F value: $13,286,354
Share change: -2,685,753
Put/Call ratio: 67%
SEC-reported price per share: $0.80
Number of holders: 42
Value change: -$3,025,814
Number of buys: 17
Number of sells: 25
Shares outstanding: 332,184,263

Security key

877619106

Report period

Q1 2023

Institutions

Top holders

TSHA full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2026 Taysha Gene Therapies, Inc. SEC filings Taysha Gene Therapies, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 877619106

Newer quarter: Q3 2026

Recent filing periods:

Q3 2026

Ownership snapshot

Top reported holders of TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Audentes Therapeutics, Inc.

Disclosed value leader

Audentes Therapeutics, Inc.

Comparable rows

0/15

Latest evidence

31 Dec 2022

3/4/5 13F Highest disclosed value: $11,844,137 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Audentes Therapeutics, Inc. has the largest disclosed position value at $11.84M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Audentes Therapeutics, Inc.'s linked filing trail.

Disclosed position value Top 5

Audentes Therapeutics, Inc. $11.84M

Nantahala Capital Management, LLC $6.78M

VANGUARD GROUP INC $3.52M

TYBOURNE CAPITAL MANAGEMENT (HK) LTD $3.39M

Artal Group S.A. $3.26M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Audentes Therapeutics, Inc.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$11,844,137 7,266,342 shares	—	21 Oct 2022
Nantahala Capital Management, LLC	13F Company 13F	— denominator unverified	$6,779,469 2,999,765 shares	—	31 Dec 2022
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$3,515,805 1,555,666 shares	—	31 Dec 2022
TYBOURNE CAPITAL MANAGEMENT (HK) LTD	13F Company 13F	— denominator unverified	$3,390,000 1,500,000 shares	—	31 Dec 2022
Artal Group S.A.	13F Company 13F	— denominator unverified	$3,256,000 1,440,882 shares	—	31 Dec 2022
Laurion Capital Management LP	13F Company 13F	— denominator unverified	$2,921,276 1,292,600 shares	—	31 Dec 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

16,687,605

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q1 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q1 2023 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend